Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | Director · Chief Executive Officer | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2026-08-12 transaction · row 30
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
24 source rowsRow 7 · 2026-08-10 · Sale · Disposed 67 · Balance 240,743 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. Row 8 · 2026-08-10 · Sale · Disposed 2,813 · Balance 237,930 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.01 to $351.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 9 · 2026-08-10 · Sale · Disposed 3,673 · Balance 234,257 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.00 to $353.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 10 · 2026-08-10 · Sale · Disposed 6,717 · Balance 227,540 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.03 to $355.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 11 · 2026-08-10 · Sale · Disposed 3,476 · Balance 224,064 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.08 to $356.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 12 · 2026-08-10 · Sale · Disposed 12,418 · Balance 211,646 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.08 to $357.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 13 · 2026-08-10 · Sale · Disposed 15,869 · Balance 195,777 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.08 to $358.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 14 · 2026-08-10 · Sale · Disposed 45,044 · Balance 150,733 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.08 to $359.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 15 · 2026-08-10 · Sale · Disposed 21,254 · Balance 129,479 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.08 to $360.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 16 · 2026-08-10 · Sale · Disposed 3,680 · Balance 125,799 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.25 to $361.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 17 · 2026-08-11 · Sale · Disposed 13,695 · Balance 112,104 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.90 to $359.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 18 · 2026-08-11 · Sale · Disposed 8,081 · Balance 104,023 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.92 to $360.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 19 · 2026-08-11 · Sale · Disposed 14,569 · Balance 89,454 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.92 to $361.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 20 · 2026-08-11 · Sale · Disposed 11,568 · Balance 77,886 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 21 · 2026-08-11 · Sale · Disposed 13,403 · Balance 64,483 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.95 to $363.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 22 · 2026-08-11 · Sale · Disposed 5,211 · Balance 59,272 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.95 to $364.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 23 · 2026-08-11 · Sale · Disposed 3,176 · Balance 56,096 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 24 · 2026-08-11 · Sale · Disposed 1,200 · Balance 54,896 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 25 · 2026-08-11 · Sale · Disposed 4 · Balance 54,892 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. Row 26 · 2026-08-12 · Sale · Disposed 1,980 · Balance 52,912 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.35 to $355.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 27 · 2026-08-12 · Sale · Disposed 2,515 · Balance 50,397 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.92 to $356.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 28 · 2026-08-12 · Sale · Disposed 15,396 · Balance 35,001 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F27: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.95 to $357.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 29 · 2026-08-12 · Sale · Disposed 20,899 · Balance 14,102 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F28: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.95 to $358.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 30 · 2026-08-12 · Sale · Disposed 14,102 · Balance 0 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F29: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.95 to $359.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,330,988 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,330,988 |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 481,533 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 481,533 F1: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 7,699,158 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,699,158 F2: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 28,204,115 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 28,204,115 F3: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 9,545,000 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 9,545,000 F4: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 102,188 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 102,188 F5: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
F2: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F3: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F4: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
F5: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership.
F6: Each American Depositary Share represents 13 Ordinary Shares.
F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.01 to $351.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.00 to $353.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.03 to $355.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.08 to $356.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.08 to $357.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.08 to $358.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.08 to $359.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.08 to $360.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.25 to $361.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.90 to $359.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.92 to $360.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.92 to $361.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.95 to $363.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.95 to $364.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.35 to $355.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.92 to $356.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F27: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.95 to $357.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F28: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.95 to $358.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F29: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.95 to $359.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 27, 2017 Filed Nov 29, 2017 22:33 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 235 | $87.49 | $20,560.15 |
DisclosureSEC source: 0001179110-17-014699 · edgar.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,462 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 22:33 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 16,346 | $86.75 | $1,418,022.04 |
DisclosureSEC source: 0001179110-17-014699 · edgar.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,697 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.27 to $87.15, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 01:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $80.84 | $8,084.00 |
DisclosureSEC source: 0001179110-17-014171 · edgar.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,043 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 01:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 62,170 | $80.29 | $4,991,790.94 |
DisclosureSEC source: 0001179110-17-014171 · edgar.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,143 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.79 to $80.77, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 01:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,798 | $79.16 | $300,632.97 |
DisclosureSEC source: 0001179110-17-014171 · edgar.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,313 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.69 to $79.64, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 01:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $81.00 | $8,100.00 |
DisclosureSEC source: 0001179110-17-014171 · edgar.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,111 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 01:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 20,407 | $80.10 | $1,634,500.71 |
DisclosureSEC source: 0001179110-17-014171 · edgar.xml · nonDerivative · entry 5 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,211 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.96 to $80.84, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 01:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 39,328 | $79.55 | $3,128,349.69 |
DisclosureSEC source: 0001179110-17-014171 · edgar.xml · nonDerivative · entry 4 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,618 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.96 to $79.95, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 01:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $84.04 | $8,404.00 |
DisclosureSEC source: 0001179110-17-014171 · edgar.xml · nonDerivative · entry 3 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,946 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 01:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 16,845 | $83.24 | $1,402,135.69 |
DisclosureSEC source: 0001179110-17-014171 · edgar.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,046 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.03 to $84.00, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 01:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 8,109 | $82.67 | $670,375.90 |
DisclosureSEC source: 0001179110-17-014171 · edgar.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,891 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.03 to $83.02, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 27, 2017 Filed Oct 2, 2017 11:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 935,000 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001179110-17-012803 · edgar.xml · derivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,000 Underlying: Ordinary Shares · 935,000 shares Expires 2027-09-26 F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F6 · shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 30, 2018, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. F6 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F6 · balance_after: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
| September 27, 2017 Filed Oct 2, 2017 11:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 515,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-012803 · edgar.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,745,525 F1 · security: Represents securities underlying restricted share units ("RSUs"). 1/4th of the securities will vest on each anniversary of June 30, 2017, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 22:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $68.11 | $20,433.00 |
DisclosureSEC source: 0001179110-17-010285 · edgar.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.00 to $68.19, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 22:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,071 | $67.36 | $206,865.02 |
DisclosureSEC source: 0001179110-17-010285 · edgar.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.98, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 22:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 51,821 | $66.35 | $3,438,255.98 |
DisclosureSEC source: 0001179110-17-010285 · edgar.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,371 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.99, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 22:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 64,553 | $65.42 | $4,222,889.42 |
DisclosureSEC source: 0001179110-17-010285 · edgar.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,192 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.99, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 22:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 44,695 | $64.51 | $2,883,234.22 |
DisclosureSEC source: 0001179110-17-010285 · edgar.xml · nonDerivative · entry 5 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,745 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.96, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 22:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 30,390 | $63.63 | $1,933,770.40 |
DisclosureSEC source: 0001179110-17-010285 · edgar.xml · nonDerivative · entry 4 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,440 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $63.99, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 22:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 10,324 | $62.57 | $646,015.01 |
DisclosureSEC source: 0001179110-17-010285 · edgar.xml · nonDerivative · entry 3 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,830 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.99, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 22:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 6,901 | $61.50 | $424,379.76 |
DisclosureSEC source: 0001179110-17-010285 · edgar.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,154 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.00 to $61.99, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 22:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,345 | $60.62 | $445,281.81 |
DisclosureSEC source: 0001179110-17-010285 · edgar.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,055 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.95, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 00:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,500 | $45.73 | $205,785.90 |
DisclosureSEC source: 0001179110-17-009627 · edgar.xml · nonDerivative · entry 5 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,840 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.29 to $46.00, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 00:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 10,981 | $44.62 | $490,000.77 |
DisclosureSEC source: 0001179110-17-009627 · edgar.xml · nonDerivative · entry 4 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,340 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.27 to $45.23, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 00:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 24,414 | $43.85 | $1,070,566.11 |
DisclosureSEC source: 0001179110-17-009627 · edgar.xml · nonDerivative · entry 3 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,321 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.08 to $44.07, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 27, 2017 00:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,800 | $44.78 | $80,611.02 |
DisclosureSEC source: 0001179110-17-009627 · edgar.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,735 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.65 to $44.80, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 27, 2017 00:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 56,805 | $44.06 | $2,502,657.89 |
DisclosureSEC source: 0001179110-17-009627 · edgar.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,535 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.50 to $44.48, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| May 01, 2017 Filed May 1, 2017 23:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,100 | $42.02 | $88,243.05 |
DisclosureSEC source: 0001104659-17-028509 · a4.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,340 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.09, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 27, 2017 Filed May 1, 2017 23:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 34,049 | $40.37 | $1,374,564.94 |
DisclosureSEC source: 0001104659-17-028509 · a4.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,440 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.63, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 20, 2017 Filed Mar 20, 2017 23:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 13,234 | $40.02 | $529,611.45 |
DisclosureSEC source: 0001104659-17-018108 · a4.xml · nonDerivative · entry 4 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,489 F1 · security: Each American Depositary Share represents 13 Ordinary Shares F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.16, inclusive. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 23:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,717 | $40.02 | $108,736.79 |
DisclosureSEC source: 0001104659-17-018108 · a4.xml · nonDerivative · entry 3 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,723 F1 · security: Each American Depositary Share represents 13 Ordinary Shares F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.10, inclusive. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 23:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $39.37 | $7,874.00 |
DisclosureSEC source: 0001104659-17-018108 · a4.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,440 F1 · security: Each American Depositary Share represents 13 Ordinary Shares F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 23:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 15,838 | $38.76 | $613,850.79 |
DisclosureSEC source: 0001104659-17-018108 · a4.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,640 F1 · security: Each American Depositary Share represents 13 Ordinary Shares F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.26 to $39.22, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the ranges set forth in footnotes (3) to (5). Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 00:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,230 | $40.78 | $172,512.09 |
DisclosureSEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 5 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,478 F1 · security: Each American Depositary Share represents 13 Ordinary Shares F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.58 to $41.09, inclusive. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 00:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 15,586 | $40.08 | $624,746.11 |
DisclosureSEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 4 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,708 F1 · security: Each American Depositary Share represents 13 Ordinary Shares F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.50, inclusive. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 00:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 8,500 | $41.02 | $348,661.50 |
DisclosureSEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 3 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,294 F1 · security: Each American Depositary Share represents 13 Ordinary Shares F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.09, inclusive. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 00:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 31,591 | $40.78 | $1,288,306.25 |
DisclosureSEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,794 F1 · security: Each American Depositary Share represents 13 Ordinary Shares F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.9901, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the ranges set forth in footnotes (3) to (6). Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 49,092 | $41.25 | $2,025,103.91 |
DisclosureSEC source: 0001104659-17-014481 · a4.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,385 F1 · security: Each American Depositary Share represents 13 Ordinary Shares F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,933 | $40.36 | $118,368.55 |
DisclosureSEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 5 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,477 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.20 to $40.87, inclusive. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,426 | $39.83 | $295,793.92 |
DisclosureSEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 4 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,410 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.19 to $40.18, inclusive. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,204 | $40.67 | $292,980.92 |
DisclosureSEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 3 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,836 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.99, inclusive. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 38,343 | $40.75 | $1,562,488.75 |
DisclosureSEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,040 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.59 to $40.94, inclusive. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 9,057 | $40.23 | $364,378.51 |
DisclosureSEC source: 0001104659-17-010630 · a4.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,383 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.59 to $40.58, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the ranges set forth in footnotes (3) to (7). Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to buy) · Derivative | 2,047,500 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001179110-16-031848 · edgar.xml · derivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,047,500 Underlying: Ordinary Shares · 2,047,500 shares Expires 2026-11-15 F2 · derivative.exercise_price: In ordinary shares. One American Depositary Share represents 13 ordinary shares. F2 · shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares. F1 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares subject to this option are subject to accelerated vesting upon a change in control or certain termination events. F2 · derivative.underlying_shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares. F2 · balance_after: In ordinary shares. One American Depositary Share represents 13 ordinary shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.